New drug Z-Endoxifen shows promise in early breast cancer trial

NCT ID NCT01327781

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a drug called Z-endoxifen in 62 people with a type of breast cancer that has spread or come back. The goal was to find the safest dose and check for side effects. Z-endoxifen works by blocking estrogen, which some breast cancers need to grow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2/NEU POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2/NEU POSITIVE RECURRENT BREAST CARCINOMA STAGE IIIC BREAST CANCER AJCC V7 STAGE IV BREAST CANCER AJCC V6 AND V7

Contacts and locations

Locations

Mayo Clinic in Arizona

Scottsdale, Arizona, 85259, United States
Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980, United States
Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.